TY - JOUR JO - Reumatologia/Rheumatology SN - 0034-6233 VL - 58 IS - 5 PY - 2020 ID - Dudek2020 TI - Mesenchymal stem cells in systemic sclerosis therapy AB - Systemic sclerosis (SSc) is a rare autoimmune disorder with a high mortality rate. There are still many unknowns concerning the pathophysiology of this disease, due to its clinical heterogeneity. Since there is still no curative treatment, researchers focus on finding novel methods to help the patients. One of the valid options is cellular therapy, and mesenchymal stem cells (MSCs)-based therapy yields great expectations. These cells possess especially valuable attributes regarding key points of SSc. Nevertheless, the effectiveness and safety of this therapy must undergo a rigorous process of veri­fication. In preclinical trials, animal models proved to be a valuable source of scientific knowledge regarding SSc. Because of that, it has been possible to test autologous or allogeneic MSCs from various sources in many clinical trials. A lot of aspects still have to be determined to assess their potential in the management of SSc, probably in association with other therapies. AU - Dudek, Daniel Witold AU - Walczuk, Ewa AU - Wajda, Anna AU - Paradowska-Gorycka, Agnieszka SP - 324 EP - 330 DA - 2020 DO - 10.5114/reum.2020.99995 UR - http://dx.doi.org/10.5114/reum.2020.99995 ER -